Moreover, in non-small cell lung cancer and gastrointestinal stromal tumors, FABP3 overexpression is notably correlated with tumor size and lymph node metastasis of advanced tumors and with remarkably shorter survival of patients [42, 43]. Here, FABP3 is linked to non-small cell lung carcinoma.